Introduction The efficacy of tiotropium/olodaterol compared with tiotropium in patients with
chronic obstructive pulmonary disease (COPD) has been demonstrated in a large clinical …

Abstract Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
strategy report recommends long-acting muscarinic antagonists (LAMA) or long-acting β 2 …

Background As lung function declines rapidly in the early stages of chronic obstructive
pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease …

Introduction Previous studies demonstrated that tiotropium/olodaterol reduced rates of
exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this …

Background Long-acting bronchodilators are the cornerstone of pharmacologic treatment of
COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) …

Background Increasing age is associated with poor prognosis in patients with COPD.
Objective This analysis from the replicate Phase III OTEMTO® and TONADO® studies …

The aim of the present study was investigate the long-term effect of tiotropium as first
maintenance respiratory medication in chronic obstructive pulmonary disease (COPD). A 4 …

Patients suffering from COPD not controlled by a single bronchodilator should be given two
bronchodilators with different mechanisms of action. Addition of a LABA to a LAMA induces …

Background The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to
measure clinical control of chronic obstructive pulmonary disease (COPD). Objective This …

Over the past decade, several large-scale clinical trials have been performed to assess the
impact of pharmacological treatments on patient-centred outcomes such as dyspnoea …